Volume 11, Issue 3 (9-2021)                   JABS 2021, 11(3): 3895-3902 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Heiat F, Hosseinzadeh R, Abyazi M, Ranjbar R, Khonche A, Heiat M. Association between COVID-19 and Gastrointestinal Manifestations and Available Treatment Options. JABS 2021; 11 (3) :3895-3902
URL: http://jabs.fums.ac.ir/article-1-2533-en.html
1- Department of Physical Education and Sport Sciences, Fasa Branch, Islamic Azad University, Fasa, Iran
2- Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
4- Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
5- Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran , mohamad.heiat@gmail.com
Abstract:   (2289 Views)
Background & Objective: Corona virus disease 2019 (COVID-19) is an emerging outbreak which has involved almost all of the countries of the world now. While the main symptoms of the disease are known to be respiratory symptoms like coughing and shortness of breath, extrapulmonary symptoms have also been reported in many cases of COVID-19. Gastrointestinal (GI) manifestations including diarrhea, nausea and vomiting, abdominal pain and liver injury are amongst the most common extrapulmonary symptoms in COVID-19 patients.
Materials & Method: We used Scopus, PubMed, and Google scholar databases for this review. The last search was run on November 21, 2020
Results: Liver injury is mostly accompanied by an elevation in AST and ALT levels and a slight increase in serum billirubin levels that is observed in approximately 14.8-53.1% of COVID-19 patients.1-29% of COVID-19 patients present nausea and vomiting and 2 to 10% develop diarrhea. Abdominal pain is seen in about 2.2-6% of COVID-19 patients and most frequently seen in severely ill patients.
Conclusion: Diarrhea, nausea, and vomiting and liver injury are the most common GI symptoms in COVID-19 patients while abdominal pain is not pretty common. There are no medications of proven efficacy to treat COVID-19 or its GI manifestations so far.
 

Full-Text [PDF 446 kb]   (840 Downloads)    
Type of Study: Review | Subject: Gastroenterology
Received: 2020/11/12 | Accepted: 2021/06/19 | Published: 2021/11/13

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advanced Biomedical Sciences

Designed & Developed by: Yektaweb

Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)